This research service covers the United States rheumatoid arthritis
pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The
focus of this study is prescription therapeutics prescribed used on top of
background standard of care. Included in the study are products of the market
and products in development, as well as patient and revenue forecasts. Market
challenges, drivers, and restraints are identified and assessed. Treatment
paradigms for rheumatoid arthritis and patient flow dynamics through lines of
therapy are also included. The market is segmented by classes of drug: tumor
necrosis factor (TNF) inhibitors, non-TNF biologics, and novel oral
disease-modifying antirheumatic drugs (DMARDs).
Total Rheumatoid Arthritis Pharmacotherapeutics Market
External Challenges: Drivers and Restraints
Forecasts and Trends
Demand Analysis
Market Share and Competitive Analysis
United States Market for Rheumatoid Arthritis Pharmacotherapeutics -
Analysis by Market Segment
TNF Inhibitor Segment Breakdown
Non-TNF Biologics Segment Breakdown
Novel Oral DMARDs Segment Breakdown
The Last Word
Three Big Predictions
Appendix
Appendix
United States Market for Rheumatoid Arthritis Pharmacotherapeutics published by Frost & Sullivan in July 5, 2012. This report consists of 110 Pages and the price starts from US $ 6000.
